Skip to main content
HWAIL PHARM. CO., LTD logo

HWAIL PHARM. CO., LTD — Investor Relations & Filings

Ticker · 061250 ISIN · KR7061250007 KO Manufacturing
Open in API
Filings indexed 274 across all filing types
Latest filing 2022-06-17 Transaction in Own Shar…
Country KR South Korea
Listing KO 061250

About HWAIL PHARM. CO., LTD

http://www.hwail.com/

Hwail Pharm. Co., Ltd. is a pharmaceutical company that specializes in the research, development, manufacturing, and distribution of Active Pharmaceutical Ingredients (APIs). The company also provides a range of finished drug formulations, including generic and patented medications, as well as functional health products. A core focus of the organization is maintaining high standards through continuous R&D investment and rigorous quality control processes to develop and produce its pharmaceutical products.

Recent filings

Filing Released Lang Actions
신탁계약에의한취득상황보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Acquisition Status via Trust Agreement' (신탁계약등에의한취득상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the company's (Hwail Pharmaceutical) purchase of its own shares through a trust contract with KB Securities. This type of filing, which reports the company's buyback activity, falls under the 'Transaction in Own Shares' category.
2022-06-17 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS). This type of filing is a mandatory disclosure for company insiders (directors/executives) to report changes in their shareholdings, which corresponds to the 'Director's Dealing' category.
2022-06-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when an insider (director or major shareholder) trades company stock. This corresponds to the 'Director's Dealing' category.
2022-05-31 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 16' equivalent in the US) used to disclose insider trading or changes in share ownership by company directors and executives. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2022-05-18 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Hwail Pharmaceutical Co., Ltd. covering the period from January 1, 2022, to March 31, 2022. It contains detailed financial statements, business overviews, and management discussions, which are characteristic of an interim/quarterly financial report. It is not an announcement of a report, but the report itself. Q1 2022
2022-05-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as an 'Insider Trading Report' or 'Director's Dealing' report) where company executives or major shareholders disclose changes in their personal shareholdings. This matches the definition for 'Director's Dealing' (DIRS).
2022-05-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.